Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Guangzhou building biopharma hub

By ZHENG CAIXIONG in Guangzhou | China Daily | Updated: 2024-10-23 09:51
Share
Share - WeChat
Employees work at a biopharmaceutical production facility in Guangzhou, Guangdong province. [CHEN JIMIN/CHINA NEWS SERVICE]

Guangzhou, capital of Guangdong province, is sparing no effort to build a global hub for innovation and development of its biopharmaceutical industry, a city official said.

This is expected to inject strong momentum into the sector in the Guangdong-Hong Kong-Macao Greater Bay Area and across the country.

The development of the biopharmaceutical industry will bring more hope and benefit a vast number of patients, said Meng Hao, deputy secretary general of the Guangzhou municipal government.

To this end, the city government will establish a 150 billion yuan ($21.5 billion) industrial investment fund to promote cooperation between major financial investment companies and local investment institutions, with a focus on investing in the biomedicine sector, Meng said.

Meng made the remarks at a news conference on promoting Guangzhou's biopharmaceutical industry on Monday.

Guangzhou has a population of nearly 24 million. It is the most populous city in the GBA, which includes nine Guangdong cities as well as Hong Kong and Macao.

The southern metropolis has about 6,800 registered medical and health institutions, including 47 major hospitals and eight national and regional medical centers.

"In the first half of this year, more than 93 million patient visits had been recorded in the city's medical institutions, and the abundant medical resources provide broad space for the transformation of achievements and market application of biopharmaceutical enterprises," she said.

Guangzhou's biopharmaceutical industry is in the top tier in the country, and the city has more than 6,500 biopharmaceutical and related enterprises, including 12 Fortune Global 500 companies, 23 listed companies and over 1,000 high-tech enterprises. These have formed biopharmaceutical industrial clusters that are playing an increasingly important role in the development of Guangzhou's pillar industry, said Meng.

The city will accord priority to the development of four major industries — biopharmaceutical, medicine, traditional Chinese medicine and high-end medical apparatus and instruments. It will also try to construct a number of key State laboratories, industrial innovation centers, manufacturing innovation centers and national engineering technology centers in the next five years, said Meng.

Guangzhou will accelerate the construction of industrial parks and zones for biopharmaceutical and related industries in the following months, she added.

Zhang Yi, deputy director and spokeswoman of the Guangzhou health commission, said the commission unveiled a series of measures in September to promote the high-quality development of innovative medical devices and support their clinical application.

"The new measures aim to promote and accelerate innovation in the biopharmaceutical industry and help develop new quality productive forces," she said.

"Meanwhile, the commission encourages research and development personnel from pharmaceutical and medical device manufacturers to connect with clinical experts in medical institutions to further improve the mechanism of medical engineering integration, collaborative innovation and information exchange through establishing clinical research beds in medical institutions and conducting medicine clinical trials," she said.

The commission will further promote the application of innovative medicines and medical devices in hospital admissions, said Zhang.

Zhao Huie, a representative from Guangzhou Medprin Regenerative Medical Technologies Co Ltd, said the new measures will help enterprises accelerate clinical applications and enhance production.

"All companies hope that their medical products can be clinically applied as soon as possible," she said.

Guangdong province is planning to boost annual revenue from its biopharmaceutical and health sector to more than 1 trillion yuan by 2027, from 663.8 billion yuan in 2023, according to an action plan issued by the provincial government earlier this month.

The action plan aims to promote high-quality development of the biopharmaceutical sector in Guangdong.

According to the action plan, Guangdong is planning to lift the total annual revenue of biopharmaceutical enterprises above a designated size — which has grown by 10 percent on average since 2018 — to 500 billion yuan by 2027.

Li Yongsi contributed to this story.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲色欲久久久久综合网| 国产精品入口麻豆免费观看| 五月天国产视频| 第四色最新网站| 国产成人欧美一区二区三区| a级毛片免费完整视频| 日本三级电电影在线看| 亚洲女初尝黑人巨高清| 精品人妻无码专区中文字幕| 国产在线乱码在线视频| 97碰在线视频| 性无码一区二区三区在线观看| 九色综合九色综合色鬼| 深夜放纵内射少妇| 啊灬啊灬啊灬岳| 黄色一级视频免费| 国产高清在线精品一区| 一本久久综合亚洲鲁鲁五月天| 日本福利视频导航| 亚洲国产品综合人成综合网站| 男人边吃奶边做边爱完整 | 久久国产精品一国产精品金尊| 欧美最猛黑人xxxx黑人猛交| 免费黄色一级电影| 蜜桃久久久久久久久久久| 国产特级毛片AAAAAA视频| 99久久人妻无码精品系列| 尤物永久免费AV无码网站| 久久久久夜夜夜精品国产| 杨晨晨脱得一二净无内裤全身| 亚洲精品456在线播放| 精品久久久久久无码国产| 国产三级久久久精品麻豆三级| 久久久久999| 国产精品视频久久| a4yy私人影院| 婷婷综合久久中文字幕蜜桃三| 中文字幕永久免费| 日韩午夜在线观看| 亚洲中文字幕无码久久| 欧美精品无需播放器在线观看|